InnoCare Pharma and Zenas BioPharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multip
InnoCare Pharma Limited and Zenas BioPharma, Inc. today announced a transformational license agreement granting Zenas global develop
October 8, 2025
by InnoCare Pharma
Drug Development: Latest Strategies to Fast-Track Innovation
The conventional drug development pipeline—from target discovery through clinical trials to regulatory approval—traditionally spans more than a decade and costs billions of dollars.
September 28, 2025
by Sadia Ajmal
Introduction of Ubiquicidin (29–41) as an Emerging Infection Imaging Agent
The diagnosis of infectious diseases continues to challenge clinicians, particularly when it comes to distinguishing active infection from sterile inflammation or malignant processes.
September 28, 2025
by Sadia Ajmal
Basic Concepts and Latest Trends in Radiation Biology: Emerging Insights and Future Directions
This article outlines the basic concepts of radiation biology—including types of radiation, mechanisms of DNA damage, repair pathways, and biological outcomes—followed by a synthesis of the latest trends shaping the field.
September 18, 2025
by Sadia Ajmal
Orphan Drugs as Strategic Assets: Lifecycle Patterns, Sales Resilience, and Market Impact
This analysis refutes the misconception of orphan drugs as niche products. Using 2025 Q1 sales data and lifecycle patterns, it demonstrates their long-term revenue resilience and strategic portfolio value.
September 12, 2025
by N55.6761
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore
InnoCare Pharma announced today that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority of Singapore for the treatment of adult patients with relapsed or refractory marginal zone lymphoma .
September 8, 2025
by PharmaSources
Fishing Peptide Blockbusters from Hormones Exploring the Evolution and Future of Hormone-Based Therapeutic Peptides
Hormone-derived peptides like semaglutide ($5.16B Q1 sales) redefine drug development through long-acting engineering. Their clinical success demonstrates the transformative potential of endogenous hormones as therapeutic blueprints.
September 5, 2025
by N55.6761
From Molecule to Market: Innovations Accelerating the Future of Drug Development
Drug discovery and development has historically been a lengthy, high risk, and costly process, often spanning more than a decade and consuming billions of dollars before a product reaches patients.
September 4, 2025
by Annie Roys
Telix 2025 Half-Year Results: Strong commercial performance enables investment for long-term growth
Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the half-year ended 30 June 2025. All figures are in USD unless stated otherwise.
August 21, 2025
by PRNewswire
Lepu Biopharma (2157.HK) announces 2025 interim results
Focusing on the field of tumor treatment, innovative biopharmaceutical company Lepu Biopharma Co., Ltd. (Lepu Biopharma or the Company, stock code: 2157.HK) announced its interim results for the first half of 2025.
August 21, 2025
by ACN Newswire
InnoCare Announces First Patient Dosed in the Registrational Trial of BCL2 Inhibitor Mesutoclax for Treatment of BTKi-treated MCL Patients in China
InnoCare Pharma announced today that the first patient has been dosed in the registrational trial of B-cell lymphoma-2 (BCL2) inhibitor mesutoclax (ICP-248) for patients with BTK inhibitor treated mantle cell lymphoma (MCL) in China.
August 21, 2025
by PharmaSources
Henlius Licenses Phase 3 Innovative HER2 ADC from GeneQuantum
Recently, Shanghai Henlius Biotech, Inc. (2696.HK) has entered into a strategic collaboration with GeneQuantum Healthcare (Suzhou) Co., Ltd. ("GeneQuantum").
August 20, 2025
by Henlius